IMV (IMV) Trading Up 15.6%

Imv Inc (TSE:IMV) shares were up 15.6% during mid-day trading on Tuesday . The stock traded as high as C$4.98 and last traded at C$4.96. Approximately 109,384 shares were traded during mid-day trading, an increase of 169% from the average daily volume of 40,664 shares. The stock had previously closed at C$4.29.

A number of analysts recently commented on IMV shares. National Bank Financial dropped their price target on IMV from C$12.00 to C$11.00 and set an “outperform” rating for the company in a research note on Tuesday, March 5th. HC Wainwright reaffirmed a “buy” rating on shares of IMV in a research note on Monday, March 25th.

The company has a market capitalization of $235.28 million and a P/E ratio of -9.46. The company has a quick ratio of 2.23, a current ratio of 2.57 and a debt-to-equity ratio of 221.17.

IMV (TSE:IMV) last announced its quarterly earnings results on Thursday, March 21st. The company reported C($0.17) EPS for the quarter, missing analysts’ consensus estimates of C($0.09) by C($0.08). The company had revenue of C$0.13 million during the quarter. On average, analysts predict that Imv Inc will post -0.28999999462963 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at


IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

See Also: What causes a recession?

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with's FREE daily email newsletter.